Last reviewed · How we verify
Placebo/CP-690,550
CP-690,550 is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory immune responses.
CP-690,550 is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory immune responses. Used for Rheumatoid arthritis, Ulcerative colitis, Psoriasis.
At a glance
| Generic name | Placebo/CP-690,550 |
|---|---|
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
CP-690,550 (tofacitinib) selectively inhibits JAK1 and JAK3 kinases, which are critical for cytokine signaling in T cells and other immune cells. By blocking these kinases, the drug suppresses the production of pro-inflammatory cytokines and reduces pathogenic T cell activation, thereby dampening autoimmune and inflammatory responses.
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
- Psoriasis
- Polyarticular course juvenile idiopathic arthritis
Common side effects
- Upper respiratory tract infection
- Headache
- Diarrhea
- Nasopharyngitis
- Elevated cholesterol
- Hypertension
Key clinical trials
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA (PHASE3)
- CP-690-550 Ointment For Chronic Plaque Psoriasis (PHASE2)
- CP-690,550 Thorough QTc Study (PHASE1)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (PHASE3)
- A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (PHASE3)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (PHASE3)
- A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo/CP-690,550 CI brief — competitive landscape report
- Placebo/CP-690,550 updates RSS · CI watch RSS
- Pfizer portfolio CI